Media coverage about Merus (NASDAQ:MRUS) has trended positive this week, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Merus earned a news impact score of 0.34 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 44.7873534885922 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
A number of equities research analysts have recently issued reports on the stock. Royal Bank of Canada cut shares of Merus from an “outperform” rating to a “sector perform” rating and set a $28.00 target price on the stock. in a report on Tuesday, January 2nd. BidaskClub upgraded shares of Merus from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 30th. Finally, Wedbush reiterated an “outperform” rating and issued a $32.00 price target on shares of Merus in a research note on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $30.25.
Shares of MRUS stock traded up $0.64 on Wednesday, reaching $18.31. 13,727 shares of the company were exchanged, compared to its average volume of 40,990. Merus has a twelve month low of $13.23 and a twelve month high of $26.20. The firm has a market cap of $352.73, a price-to-earnings ratio of -3.34 and a beta of 0.09.
COPYRIGHT VIOLATION WARNING: This news story was first published by BBNS and is owned by of BBNS. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://baseballnewssource.com/2018/03/21/positive-press-coverage-somewhat-unlikely-to-impact-merus-mrus-stock-price/1922628.html.
Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.